Detalhe da pesquisa
1.
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Mov Disord
; 38(3): 386-398, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807624
2.
Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Int J Mol Sci
; 21(15)2020 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32707880
3.
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
J Clin Psychopharmacol
; 36(4): 314-23, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27253658
4.
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.
Mov Disord
; 30(7): 919-27, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25737166
5.
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.
Int J Clin Pharmacol Ther
; 52(8): 631-41, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24800921
6.
Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.
Hum Psychopharmacol
; 28(2): 124-33, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23532746
7.
No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters.
Int J Clin Pharmacol Ther
; 51(12): 976-85, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24120718
8.
A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
Clin Transl Sci
; 16(8): 1408-1420, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37177855
9.
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Clin Transl Sci
; 15(8): 2010-2023, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35649245
10.
Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.
J Exp Med
; 219(3)2022 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35226042
11.
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
Sci Transl Med
; 14(648): eabj2658, 2022 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35675433
12.
Safety, Tolerability, and Pharmacokinetics of the ß-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
Clin Transl Sci
; 12(5): 545-555, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31215755
13.
Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
Clin Pharmacol Ther
; 105(5): 1234-1243, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30347431
14.
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
J Clin Pharmacol
; 48(2): 209-14, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18077730
15.
Asenapine pharmacokinetics and tolerability in a pediatric population.
Drug Des Devel Ther
; 12: 2677-2693, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30214156
16.
Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis.
J Neurosci
; 26(46): 11915-22, 2006 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17108165
17.
Alpha-synuclein overexpression increases cytosolic catecholamine concentration.
J Neurosci
; 26(36): 9304-11, 2006 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-16957086
18.
Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
J Clin Sleep Med
; 12(1): 9-17, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26194728
19.
On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
Psychopharmacology (Berl)
; 233(18): 3341-51, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27424295
20.
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS ß-amyloid in animal models and in Alzheimer's disease patients.
Sci Transl Med
; 8(363): 363ra150, 2016 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27807285